Medical Oncologist at IRCCS Istituto Nazionale Tumori di Milano @IstTumori - Genitourinary Medical Oncology Department
Joined October 2021
- Tweets40
- Following92
- Followers48
- Likes40
Alessandro Rametta retweeted
First in-person meeting of the #pRCCTREAT consortium at @IIBmCSICUAM , Madrid!
Two days of great discussions, collaboration and planning to advance research in papillary renal cell carcinoma. Excited for what's ahead! 🔬 #KidneyCancer #personalisedmedicine
Alessandro Rametta retweeted
New insights into Lynch syndrome-associated urothelial cancer: molecular profiling reveals frequent #FGFR3 alterations, highlighting potential therapeutic vulnerabilities in this rare disease.
Full article: doi.org/10.1007/s10689-026-0…
#LynchSyndrome #UrothelialCancer
Alessandro Rametta retweeted
🔬 New evidence in #mHSPC
PSA nadir ≤0.2 ng/mL was strongly associated with better outcomes:
📈 OS: 92.8 vs 34 mo (HR 0.27)
📈 PFS: NR vs 12.1 mo (HR 0.19) Supporting PSA nadir as an early prognostic marker. #ProstateCancer #GUOncology
Full Article: rdcu.be/fyxRQ
Alessandro Rametta retweeted
New data in @ESMO_Open : among 59 centrally reviewed collecting duct carcinoma cases, Trop-2 was expressed in 89% and Nectin-4 in 41%, supporting further investigation of antibody-drug conjugates in this rare disease.
doi.org/10.1016/j.esmoop.202…
#KidneyCancer #RareCancer
Alessandro Rametta retweeted
Does local treatment of the primary tumour still add value in #mHSPC patients receiving ARPIs? Our latest expert opinion examines the evidence, ongoing controversies and future directions in the intensification era.
Article here: tandfonline.com/doi/full/10.…
#Genitourinary #Prostate
Alessandro Rametta retweeted
The 3rd General Assembly of the European @CARE1Project has officially started today @IstTumori!
Partners from across Europe are meeting to share progress and strengthen collaboration in kidney cancer research
#CARE1 #KidneyCancer #Oncology #CancerResearch #EUProjects
Alessandro Rametta retweeted
🔟 Must-Read Posts in GU Oncology | May 1–10
OncoDaily GU highlights key updates across prostate, bladder, kidney, testicular, and penile cancers.
This week:
• PSMAfore / Pluvicto — regulatory update in earlier-line mCRPC
• DEAR-EXT — real-world AR inhibitor analysis in nmCRPC
• P-PSMA-101 CAR T — Phase I study in mCRPC
• ¹⁷⁷Lu-PSMA-617 — review on immune modulation
• Radiorecurrent prostate cancer — salvage local therapies
• Stage IIIC poor-risk testicular GCT — high-risk cohort
• AI in bladder cancer — clinical decision-making
• NBI-guided diode laser ablation — recurrent low-grade NMIBC
• Metastatic non-clear cell RCC — multicenter retrospective analysis
• B7-H3/CD276 in penile cancer — bispecific antibody strategy, including CC-3
@nealshore @Igor__Tsaur @DrShariat @alerametta
@g_procopio_ @marcos130990 @Sebastiano_Buti @crisuarez08 @therealmarcodoc @fmassari79 @DrIacovelli @MatteoSantoniMD @CMucciarini_Dr
@g_procopio_ @drenriquegrande @YLeyfman @oncodaily
📎 oncodaily.com/oncolibrary/10…
#OncoDailyGU #GUOncology #ProstateCancer #BladderCancer #KidneyCancer #UroOncology
Our study is now online!
“International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma” is now published in @TumoriJ.
👉 doi.org/10.1177/030089162614…
A large international retrospective analysis of metastatic non–clear cell RCC based on Vall d’Hebron and Italian Meet-URO network @meeturoIT.
Thanks to all co-authors and collaborators!
@g_procopio_ @marcos130990 @Sebastiano_Buti @crisuarez08 @therealmarcodoc @fmassari79 @DrIacovelli @MatteoSantoniMD @CMucciarini_Dr
Alessandro Rametta retweeted
New publication where we explore the rationale and clinical implications of continuing angiogenesis inhibition beyond progression in #mRCC.
Full article here:
pubmed.ncbi.nlm.nih.gov/4191…
#ClinicalResearch #Genitourinary #oncology
Alessandro Rametta retweeted
🧵New commentary in @JCOOP_ASCO on metastatic Renal Cell Carcinoma:
“Never Stop the Pressure” 🔬
Should we keep anti-angiogenic therapy going beyond progression?
We think YES — and here’s why👇
ascopubs.org/doi/pdf/10.1200…
w/ @alerametta @elena_verzoni @g_procopio_
4 febbraio – Giornata mondiale contro il cancro.
Prevenzione, vaccinazioni e screening riducono il rischio oncologico e permettono diagnosi precoci. Sono strumenti semplici e disponibili, che possono fare la differenza.
Machine Learning to predict response to IO in 438 patients with metastatic urothelial carcinoma from Italian @meeturoIT network. Results are exploratory but clinically coherent.
AI can play an important role in GU oncology. Better data quality and wider implementation of these approaches are essential.
Thanks to @PrelajArsela, @polimi and all the @AI_ON_Lab for this work.
@giannatempopatr @g_procopio_ @marcos130990 @AndreaNecchi @Vanja_Miskovic_
Out on ESMO RWD and DO: sciencedirect.com/science/ar…
Alessandro Rametta retweeted
Innovation talk at @IstTumori with @alerametta: machine learning and artificial intelligence in GU tumors, how data and algorithms can improve diagnosis and treatment.
#AIinMedicine #ClinicalResearch #Oncology #Genitourinary #ScientificEvent #ControversiesinGU2026
Alessandro Rametta retweeted
A full day of debate, evidence and shared perspectives comes to an end at @IstTumori. Thank you to all speakers, participants and partners for contributing to "Controversies in Genitourinary Tumors". See you next year!
#ClinicalResearch #GUoncology #ControversiesinGU2026
How do we actually treat non–clear cell RCC today?
Our practical overview of systemic therapies across rare renal cancer histologies.
tandfonline.com/eprint/FKBUJ…
@g_procopio_ @elena_verzoni @marcos130990 @MelClaps @valentina79g @nzzmda @Simorota6 @elegusma
Alessandro Rametta retweeted
A review in @NatRevClinOncol @scocmem covers whats next for FGFR in bladder cancer. FORAGER-2 explores EV + pembro + Vepugratinib (FGFR inhibitor with short half life) in 1st line FGFR3 altered advanced UC. Targeted/ADC/PD1 triplets curing UC? @OncoAlert @DrChoueiri @PGrivasMDPhD
2/5 FGFR3 = the only established predictive biomarker but ⬆️ variability in detection methods (DNA/RNA, PCR, ctDNA).
Promising randomised ph3 in 1L (FORAGER-2) and NMIBC (MoonRISe-1).
@drpatrick @cdanicas @IyerGopa @OncoAlert @JanssenOncUS @DrYukselUrun @PGrivasMDPhD
Alessandro Rametta retweeted
#ESMO25 #MIBC #BladderCancer
➡️ Perioperative Pembro + EV.
😶 No words.
👏🏼 Just applause.
📣 Sound On.
@myESMO
Alessandro Rametta retweeted
1/2 Disitimab Vedotin & toripalimab beating platinum chemotherapy in 1st line UC in HER2 +ves. HRs for PFS/OS =0.36/0.56 respectively. RR and CR rate of 76% & 5% respectively. Tox related discontinuation in 12 vs 10% respectively. Working across all subsets #ESMO25 @OncoAlert
Alessandro Rametta retweeted
📢 Our case report on metastatic Leydig cell tumor treated with CDK4 inhibition is now published in JCO Precision Oncology!
👉 doi.org/10.1200/PO-25-00290
A collaborative effort with @JCOPO_ASCO @giannatempopatr @nicolanicolai @AndreaNecchi @montypal
